Yesterday at the Straumann Corporate Forum, Prof. Stephen Chen showed in his presentation (“Scientific evidence and clinical benefits of Roxolid implants”) the impressive evidence for Roxolid, Straumann’s high-strength implant material, and its clinical benefits. Roxolid SLActive is Straumann’s answer to the demand for long-lasting products, that can help to reduce treatment complexity and the need for invasive grafting procedures. With this unique material-surface combination, Straumann (Booth D01) is setting new standards, contributes to reducing the invasiveness of implant treatments and can offer clinicians the possibility to broaden their treatment options.

With Roxolid, Straumann has developed a unique material for dental implants that offers even more strength than titanium implants. As a result, Straumann implants made from Roxolid can be used when smaller implants are necessary due to insufficient bone—bone augmentation procedures can be avoided and treatment time may be reduced as the surgery requires fewer steps. By using smaller implants, this leaves more vital bone, better blood flow, and more soft tissue around the implant. These conditions are vital for the successful integration of the implant and its longevity.

Straumann has researched the possibilities of reducing healing time after insertion and enhancing predictability of the outcome, without risk to the implant integration. The result: Straumann SLActive, the clinically proven, true hydrophilic implant surface. SLActive reduces the risk during the critical early treatment by accelerating and optimizing implant integration. The bone formation process is initiated at an earlier stage, resulting in increased predictability of the outcome, without risk to the implant integration. The bone formation process is initiated at an earlier stage, resulting in improved implant stability. With conventional surfaces, implants are exposed to a higher risk of failure due to an overall stability dip within the first weeks of healing. This risk is greatly reduced with SLActive technology.

The benefits Roxolid SLActive implants have to offer are numerous: by supporting the elimination of invasive grafting procedures, clinicians can reduce the treatment time, preserve vital peri-implant structures, and decrease postsurgical complications. Furthermore, the avoidance of GBR procedures can help to increase patient acceptance of dental implant treatments resulting in an increasing number of patients that are willing to undergo implant treatment. Patients who can be treated with Roxolid SLActive implants without grafting can benefit from a less traumatic, less expensive and shorter treatment with a lifelong implant solution—all Straumann implants are covered by a lifelong warranty.

Straumann caused quite a bit of excitement at the beginning of the year with a major reorientation of its product and pricing strategies. Implantologists worldwide can now access these innovative benefits because all soft tissue and bone level implants from Straumann are sold with Roxolid at no extra cost. These new Straumann Roxolid SLActive implants are offered for the same price as the existing titanium implants. In this context, because Roxolid has been regarded as a significant milestone in modern implantology by renowned clinicians, some even expect to see Roxolid replace titanium as the material of choice over time.